FDA-cleared profile

Eclipse II with Smart Noise Cancellation

Carestream Health, Inc. · X-ray/Radiography · FDA-cleared (510(k))

Digitally enhances adult and pediatric radiographic x-ray images; mammography is excluded.

Clinical role
Image processing within the ImageView application software: an optional CNN-based noise cancellation module suppresses noise before enhancement of CR and DR radiographs, presenting images with proper quality attributes to help radiologists and physicians make a diagnosis.
Images and patients
X-ray/Radiography
Key limitation
Non-standalone ImageView module for CR/DR projection radiography; mammography is excluded; additional exact limits are unknown.

Overview status: Field-derived fact summary This section is assembled from the sourced field records below; it is not a source-reviewed editorial overview.

Report a correction
Clinical details Purpose, workflow fit, evidence, and safety record

Workflow navigation pilot

Workflow role has not yet been reviewed for this navigation pilot.

A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources

  • Imaging and anatomyX-ray/Radiography
  • Workflow roleImage processing within the ImageView application software: an optional CNN-based noise cancellation module suppresses noise before enhancement of CR and DR radiographs, presenting images with proper quality attributes to help radiologists and physicians make a diagnosis.
  • Required inputProjection-radiography acquisitions from computed-radiography or digital-radiography receptors.
  • Output and human actionA digitally enhanced radiographic image, with noise suppression before enhancement and an estimated-noise 2D Noise Field used in processing.

Evidence context

Evidence context not reviewed for this FDA record.

Public-label constraints

Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.

Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.

Purpose
Digitally enhances adult and pediatric radiographic x-ray images; mammography is excluded.
  • Exact FDA submission
  • Checked 2026-09-19

Clinical-use display mirrors the exact FDA-supported purpose reconciled in this remediation finding.

Workflow role
Image processing within the ImageView application software: an optional CNN-based noise cancellation module suppresses noise before enhancement of CR and DR radiographs, presenting images with proper quality attributes to help radiologists and physicians make a diagnosis.
  • Exact FDA submission
  • Checked 2026-11-14

Packet wording: "Eclipse software runs inside the ImageView product application software (not considered stand-alone software). Smart Noise Cancellation is an optional feature (module) that enhances projection radiography acquisitions captured from digital radiography imaging receptors (Computed Radiography (CR) and Digital Radiography (DR)." … "The difference in the modified software is the implementation of noise suppression prior to enhancement processing. The Smart Noise Cancellation operation passes the acquired preprocessed image through a specially trained Convolutional Neural Network (CNN)". Read from the exact FDA decision document on 2026-11-14.

Required input
Projection-radiography acquisitions from computed-radiography or digital-radiography receptors.
  • Exact FDA submission
  • Checked 2026-09-19

FDA device description and technological-characteristics scope.

Output and clinician action
A digitally enhanced radiographic image, with noise suppression before enhancement and an estimated-noise 2D Noise Field used in processing.
  • Exact FDA submission
  • Checked 2026-09-19

FDA device description.

Care setting
Adult and Pediatric
  • Exact FDA submission
  • Checked 2026-09-01

Patient-population text reported in the exact-submission ACR model card; institutional setting may still require vendor confirmation.

Intended users
Radiologists and physicians.
  • Exact FDA submission
  • Checked 2026-09-19

FDA packet user scope.

Limitations
Non-standalone ImageView module for CR/DR projection radiography; mammography is excluded; additional exact limits are unknown.
  • Exact FDA submission
  • Checked 2026-09-19

Exact packet boundary; no broader scanner or anatomy claim.

Evidence summary
FDA summary reports no additional non-clinical testing and a concurrence study using visual-difference and RadLex scales; it reports 50% CsI and 40% GOS dose-reduction testing, with sample size and sites unknown.
  • Exact FDA submission
  • Checked 2026-09-19

Submission-reported testing only; not independent validation.

Evidence

Performance evidence

Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.

Evidence summary
FDA summary reports no additional non-clinical testing and a concurrence study using visual-difference and RadLex scales; it reports 50% CsI and 40% GOS dose-reduction testing, with sample size and sites unknown.
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-19

Submission-reported testing only; not independent validation.

Reported sensitivity
Research pending
  • Needs research
  • Exact FDA submission
  • Checked 2026-08-31

This field has not been curated yet.

Reported specificity
Research pending
  • Needs research
  • Exact FDA submission
  • Checked 2026-08-31

This field has not been curated yet.

No contextualized exact-version metric has completed evidence review. Regulatory-document values, when available, are shown above with their limitations.

Eclipse II with Smart Noise Cancellation regulatory performance study summary

  • DesignStand-Alone Performance
  • PopulationAdult and Pediatric
  • Scopeexact submission
  • Tested versionExact product version not reported; regulatory study summarized for FDA submission K213307
  • IndependenceIndependence not established

K213307

ACR AI Central summarizes the regulatory study; consult the exact FDA materials before comparative use.

Safety and lifecycle

Postmarket record

Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.

Postmarket safety review
The exact-identifier FDA recall query returned no native recall record for K213307. This limited result does not establish absence of recalls or other safety information and does not cover later versions, family records, MAUDE reports, corrections, or field notices.
  • Public source
  • Exact FDA submission
  • Checked 2026-09-09
Pricing & contracts Public price, contract terms, and reimbursement

Price not public here; enter your quote

Not verified: Pricing information is recorded but not verified against a resolving source.

Reimbursement

IT implementation Deployment, interfaces, data handling, and support

System and version relationships

Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.

No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.

Review Merge, Visage, Sectra, AGFA and IntelePACS context

Integration chain: evidence at each hop

Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.

Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner

No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.

  1. Acquisition/source

    Source context, not route validation: Projection-radiography acquisitions from computed-radiography or digital-radiography receptors.

    Scope: Exact FDA submission. FDA device description and technological-characteristics scope.

    Confirm scanner/model, protocol, series completeness and both software builds.

    Field checked 2026-09-19 · FDA K213307: Eclipse II with Smart Noise Cancellation

  2. Routing

    Unresolved route: Not established for the exact route.

    Scope: Exact FDA submission. The exact FDA decision document was reviewed on 2026-11-14 and does not state the subject device's DICOM, PACS, RIS, or EHR interfaces. Confirm supported DICOM services and PACS, RIS, EHR, and interface versions with the vendor.

    Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.

    Field checked 2026-11-14 ·

  3. AI processing

    Unresolved route: Not established for the exact route.

    Scope: Exact FDA submission. The reviewed sources do not establish the current exact-release hosting topology, data flow, region, tenancy, or disaster-recovery configuration.

    Confirm processing location, queue ownership, exclusions and exact AI build.

    Field checked 2026-09-09 ·

  4. Returned objects

    Source context, not route validation: A digitally enhanced radiographic image, with noise suppression before enhancement and an estimated-noise 2D Noise Field used in processing.

    Scope: Exact FDA submission. FDA device description.

    Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.

    Field checked 2026-09-19 · FDA K213307: Eclipse II with Smart Noise Cancellation

  5. Viewer/worklist/report

    Unresolved route: A digitally enhanced radiographic image, with noise suppression before enhancement and an estimated-noise 2D Noise Field used in processing.

    Scope: Exact FDA submission. FDA device description.

    Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.

    Field checked 2026-09-19 · FDA K213307: Eclipse II with Smart Noise Cancellation

  6. Support owner

    Unresolved route: Not established for the exact route.

    Scope: Scope not established.

    Name the local, platform and AI supplier support owners and escalation path.

Planned local route tests

No tests below have been performed or accepted.

  1. Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
  2. Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
  3. Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
  4. Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
  5. Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
  6. Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
  7. Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.

Local implementation checklist

Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.

Open the printable evaluation checklist

Security
Carestream Health's cybersecurity and privacy page describes a product security program: coordinated vulnerability disclosure, MDS2 statements, published product security advisories with patch information, security configuration documentation for product operating systems, and a customer service portal providing security advisories, updates, network maps, SBOM, firewall and group-policy configuration.
  • Vendor-wide
  • Checked 2026-10-27

Vendor statement; portal content is customer-gated. Applied only to Carestream Health, Inc. entries; CARESTREAM DENTAL LLC is a separate company and was not bridged. Exact-release scope is not established.

Monitoring
Carestream Health's cybersecurity and privacy page states a coordinated vulnerability disclosure process, product security advisories with patch information, OS security configuration documentation, and a customer portal carrying advisories, updates, network maps, SBOM and firewall/group-policy configuration.
  • Vendor-wide
  • Checked 2026-10-27

Vendor statement, not an attestation. The page names Carestream Health generally and does not scope these commitments to any specific product release; exact-release scope is not established. The customer portal is customer-gated; its contents were not read.

Supported acquisition environment

Scanner manufacturers: All

exact submission · checked 2026-09-01

Confirm currently supported software versions, protocols, and site-specific acquisition configurations.

ACR exact-submission catalog context

ACR AI Central provides an exact-submission model card for Eclipse II with Smart Noise Cancellation; FDA labeling remains controlling for clinical use, limitations, and performance.

exact submission · checked 2026-09-09
Sources & review details FDA identity, research record, source ledger, and history

Regulatory identity

FDA record and catalog context

The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.

FDA submission
K213307
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Modality
X-ray/Radiography
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-19

Projection radiography and CR/DR detector scope normalized to the controlled catalog modality.

Anatomy
Value withdrawn pending re-verification
  • Corrected record
  • Exact FDA submission
  • Checked 2026-09-19

Previous value withdrawn: The exact FDA decision-summary packet reviewed on 2026-09-19 does not establish this claim.

Clearance type
510(k)
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Decision date
2022-01-14
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
FDA status
FDA-cleared
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31

Research record

What has been checked

This audit distinguishes completed source review from fields that have not yet been researched.

Exact FDA record reviewedStatus
2026-09-19Last searched
23Fields reviewed
10Source classes checked
0Awaiting review PubMed leads
0Awaiting review trial leads
0Unreviewed FDA recall leads

Exact-submission ACR model-card fields were normalized under the current provenance rules; vendor and independent-study confirmation remain distinct. Exact FDA decision-summary packet reviewed on 2026-09-19. Applied FDA-supported reader facts: purpose, modality, intendedUsers, input, output, limitations, evidenceSummary. Facts marked unknown in the FDA packet retain any prior non-FDA source without reclassification. Candidate literature and postmarket candidates remain in their existing review state. Automated exact-name discovery found 0 PubMed and 0 ClinicalTrials.gov candidate records. Candidates require human product and version matching; zero candidates is not evidence that no studies exist. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.

Candidate leads remain unpublished until a human confirms the exact product and tested version.

Source classes: fda ai list, fda decision summary, acr ai central product, fda device recall, literature index, trial registry, fda decision summary packet, pubmed, clinical trials, openfda device recall

Field review details

Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.

  • Public pricing: Not verified - checked 2026-09-09 - Exact FDA submission

    No public price or quote for the exact K213307 configuration was established in this review.

  • Pricing model: Not yet reviewed
  • Setup and integration fees: Not yet reviewed
  • Recurring fees: Not yet reviewed
  • Minimum commitment: Not yet reviewed
  • Contract duration: Not yet reviewed
  • Renewal terms: Not yet reviewed
  • Cancellation terms: Not yet reviewed
  • Support and service terms: Not yet reviewed
  • Trial or pilot terms: Not yet reviewed
  • Reimbursement: Not publicly available - checked 2026-09-09 - Exact FDA submission

    No exact-product payer policy, coding instruction, or payment determination was established; eligibility must be evaluated by payer, site of service, and use case.

  • Deployment: Not verified - checked 2026-09-09 - Exact FDA submission

    The reviewed sources do not establish the current exact-release hosting topology, data flow, region, tenancy, or disaster-recovery configuration.

  • Integration: Not publicly available - checked 2026-11-14 - Exact FDA submission

    The exact FDA decision document was reviewed on 2026-11-14 and does not state the subject device's DICOM, PACS, RIS, or EHR interfaces. Confirm supported DICOM services and PACS, RIS, EHR, and interface versions with the vendor.

  • Data hosting location: Not yet reviewed
  • Data retention: Not yet reviewed
  • Documented data use: Not yet reviewed
  • Hardware requirements: Not yet reviewed
  • Network requirements: Not yet reviewed
  • Identity and access: Not yet reviewed
  • Installation timeline: Not yet reviewed
  • Training: Not verified - checked 2026-09-09 - Exact FDA submission

    Current training prerequisites, competency checks, and support commitments for the exact configuration require vendor confirmation.

8 sources - 2 history items

Source ledger

  1. FDA K213307: Eclipse II with Smart Noise Cancellation

    U.S. Food and Drug Administration - Published 2022-01-14 - Accessed 2026-09-09

    Scope: identity, clinicalUse, modality, anatomy, workflow, evidence, implementation, purpose, intendedUsers, input, output, limitations, evidenceSummary

  2. Artificial Intelligence-Enabled Medical Devices

    U.S. Food and Drug Administration - Accessed 2026-08-31

    Scope: regulatoryIdentity, modalityContext

  3. Eclipse II with Smart Noise Cancellation model card (K213307)

    American College of Radiology - Published 2026-08-17 - Accessed 2026-09-01

    Scope: intendedUsers, careSetting, output, limitations, evidenceSummary, anatomy, evidenceStudies, implementationCapabilities

  4. PubMed biomedical literature index

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery

  5. ClinicalTrials.gov study registry

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery, studyStatus

  6. openFDA Device Recall API

    U.S. Food and Drug Administration - Accessed 2026-09-02

    Scope: recallDiscovery, nativeSubmissionMatching

  7. openFDA exact recall query for K213307

    U.S. Food and Drug Administration - Accessed 2026-09-09

    Scope: postmarketSafety

  8. Carestream Health: Cybersecurity and Privacy

    Carestream Health - Accessed 2026-10-27

    Scope: security

Research history

  1. K213307 FDA decision

    Regulatory record

    510(k)

  2. Source-review record updated

    Research record

    fda record reviewed

Alternatives

Related tools to compare

FDA-cleared K251167

uDR Aurora CX

Shanghai United Imaging Healthcare Co., Ltd.

Authorized purpose: uDR Aurora CX acquires two-dimensional X-ray images of the labeled skull, spine, chest, abdomen, extremities, limbs, and trunk for review by qualified healthcare professionals; it is not a mammography system.

Modality
X-ray/Radiography
Anatomy
Skull, spine, chest, abdomen, extremities, limbs, and trunk
Decision
2025-09-19
FDA-cleared K202441

Eclipse II with Smart Noise Cancellation

Carestream Health, Inc.

Authorized purpose: Eclipse II with Smart Noise Cancellation digitally enhances radiographic images generated by supported X-ray devices for adult and pediatric use; the cleared function is for projection radiography and excludes mammography.

Modality
X-ray/Radiography
Anatomy
Adult and pediatric radiographic anatomy excluding mammography
Decision
2021-04-02
FDA-cleared K133259

YSIO MAX

SIEMENS MEDICAL SOLUTIONS USA, INC.

Authorized purpose: YSIO MAX is a digital radiography system for whole-body skull, chest, abdomen, and extremity imaging in pediatric, adult, and bariatric patients, including supported emergency and small-intervention positions; it is not a mammography system.

Modality
X-ray/Radiography
Anatomy
Multi-region
Decision
2014-01-24
FDA-cleared K253172

MediAI-OA

Crescom Co., Ltd.

Authorized purpose: Assist trained professionals in assessing radiographic knee osteoarthritis and its sclerosis, joint-space-narrowing, and osteophyte features on standing fixed-flexion knee radiographs.

Modality
X-ray/Radiography
Anatomy
Knee joint
Decision
2026-06-15

Correct this exact record

Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.

Open existing correction destination

Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.

Accepted repository change history

No entry has been added to this scoped change history for this record. This is not proof that the record never changed.

Correction policy and limits · Public repository change history